BioNexus Gene Lab Corp. (BGLC)
NASDAQ: BGLC · Real-Time Price · USD
2.540
+0.290 (12.89%)
Mar 17, 2026, 4:00 PM EDT - Market closed

BioNexus Gene Lab Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-2.3-1.6-2.63-0.360.751.09
Depreciation & Amortization
0.170.150.110.110.110.1
Other Adjustments
0.08-0.90.58-0.030.01-0.75
Change in Receivables
-0.160.150.650.540.580.41
Changes in Inventories
0.38-0.25-0.160.54-0.350.15
Changes in Accounts Payable
-0.770.2-0.38-0.12-1.18-0.52
Changes in Income Taxes Payable
-0.1-0.04-0.040.010.070.03
Changes in Unearned Revenue
-0.010.1-0.02-0.080.11-
Changes in Other Operating Activities
-0.05-0.040.08-0.06-0.090.04
Operating Cash Flow
-2.87-2.23-1.820.550.010.55
Operating Cash Flow Growth
---5923.60%-98.34%-
Capital Expenditures
-0.04-0.23-0.15-0.05-0-0.42
Sale of Property, Plant & Equipment
-----1.47
Purchases of Investments
-0.08-0.57-1.73-0.51-0.52-0.11
Proceeds from Sale of Investments
1.591.070.03-0.010.03
Other Investing Activities
0.030.150.060.120.020.35
Investing Cash Flow
1.440.42-1.79-0.45-0.491.32
Long-Term Debt Repaid
----0.03-0.03-0
Net Long-Term Debt Issued (Repaid)
----0.03-0.03-0
Issuance of Common Stock
--5.750.15--
Repurchase of Common Stock
-0-----
Net Common Stock Issued (Repurchased)
-0-5.750.15--
Other Financing Activities
0.030.140.52-0.01-0-
Financing Cash Flow
0.180.146.270.11-0.03-0
Effect of Exchange Rate Changes on Cash and Cash Equivalents
-0.120.04-0.26-0.21-0.150.06
Net Cash Flow
-1.37-1.632.4-0.01-0.661.93
Free Cash Flow
-2.91-2.46-1.970.50.010.13
Free Cash Flow Growth
---8195.57%-95.42%-
FCF Margin
-30.74%-25.88%-20.18%4.55%0.04%1.15%
Free Cash Flow Per Share
-0.13-0.14-0.120.350.000.15
Levered Free Cash Flow
-2.7-1.7-3.2-0.04-0.610.46
Unlevered Free Cash Flow
-2.76-1.68-3.170-0.580.48
Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q